Age associated increase in the prevalence of chromosome 22q loss of heterozygosity in histological subsets of benign meningioma

Journal of Medical Genetics

Volumn 43, Issue 3, 2006, Pages 285-287

  Baser, M E ^a   Poussaint, T Y ^b  

^a Harvard Medical School ^*

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ALLELE; ARTICLE; BENIGN TUMOR; CHROMOSOME 22Q; CONTROLLED STUDY; FEMALE; GENE NF2; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; NEUROFIBROMATOSIS; PREVALENCE; PRIORITY JOURNAL; RISK; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

AGED; CHROMOSOMES, HUMAN, PAIR 22; HUMANS; LOSS OF HETEROZYGOSITY; MENINGEAL NEOPLASMS; MENINGIOMA; NEUROFIBROMIN 2; REGRESSION ANALYSIS;

EID: 33645118444     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2005.035162     Document Type: Article

References (33)

1. Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000;54:71-6.
2. Krampla W, Newrkla S, Pfisterer W, Jungwirth S, Fischer P, Leitha T, Hruby W, Tragl KH. Frequency and risk factors of meningioma in clinically healthy 75-year-old patients: results of the Transdanube Ageing Study (VITA). Cancer 2004;100:1208-12.
3. McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, Mench HR, Laws ER Jr. Factors associated with survival in patients with meningioma. J Neurosurg 1998;88:831-9.
4. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K, Haase VH, Ambrose CM, Munroe D, Bove C, Haines JL, Martuza RL, MacDonald ME, Seizinger BR, Short MP, Buckler AJ, Gusella JF. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800.
5. Rouleau GA, Mérel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, Pulst SM, Lenoir G, Bijlsma E, Fashold R, Dumanski J, de Jong P, Parry D, Eldridge R, Aurias A, Delattre O, Thomas G. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-21.
6. Mérel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, Moisan JP, Resche F, Nishisho I, Estivill X, Delattre JY, Poisson M, Theillet C, Hulsebos T, Delattre O, Thomas G. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chrom Cancer 1995;13:211-10.
7. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, von Deimling A. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995;146:827-32.
8. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1997;6:180-4.
9. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol 2004;70:183-202.
10. Dumanski JP, Rouleau GA, Nordensköld M, Collins VP. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 1990;50:5863-7.
11. Leone PE, Bello MJ, de Campos JM, Vaquero J, Sarasa JL, Pestana A, Rey JA. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18:2231-9.
12. Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne dit Deprez R, Zwarthoff E. NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 2001;194:367-72.
13. Lekanne Deprez RH, Riegman PH, van Drunen E, Warringa UL, Goren NA, Stefanko SZ, Koper JW, Avezaat CJJ, Mulder PGH, Swarthoff EC, Hagemeijer A. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 1995;54:224-35.
14. Weber RG, Boström J, Wolters M, Baudis M, Collins VP, Reifenberger G, Lichter P. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719-24.
15. Baser ME, International NF2 Mutation Database Contributors. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat (in press).
16. Papi L, De Vitis LR, Vitelli F, Ammannai F, Mennonna P, Montali E, Bigozzi U. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 1995;95:347-51.
17. Ng H-k, Lau K-m, Tse JYM, Lo K-w, Wong JHC, Poon W-s, Huang DP. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 1995;37:764-73.
18. Kim J-H, Lee S-H, Rhee C-H, Park S-Y, Lee J-H. Loss of heterozygosity on chromosome 22q and 17p correlates with aggressiveness of meningiomas. J Neuro-Oncol 1998;40:101-6.
19. van Tilborg AAG, Al Allak B, Velthuizen CJM, de Vries A, Kros JM, Avezaat CJJ, de Klein A, Beverloo HB, Zwarthoff EC. Chromosomal instability in meningiomas. J Neuropathol Exp Neural, 2005;64, 312-22.
20. Moragoda L, Jaszewski R, Kuldarni P, Majumdar APN. Age-associated loss of heterozygosity of tumor suppressor genes in the gastric mucosa of humans. Am J Physiol Liver Physiol 2002;282:G932-6.
21. Evans JJ, Jeun S-S, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, Golubic M. Molecular alterations in the neurofibromatosis Type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg 2001;94:111-17.
22. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst S-M. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 1994;3:885-91.
23. Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res, 1999;59:5995-8.
24. Wellenreuther R, Waha A, Vogel Y, Lennartz D, Schramm J, Wiestler OD, von Deimling A. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 1997;77:601-6.
25. Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubić M. Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery 1997;40:578-87.
26. Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, Fukui M, Tateishi J. Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 1997;93:225-32.
27. Carlson KM, Bruder C, Nordenskjold M, Dumanski JP. 1p and 3p deletions in meningiomas without detectable aberrations of chromosome 22 identified by comparative genomic hybridization. Genes Chrom Cancer 1997;20:419-24.
28. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH. Merlin, DAL-1, and progesterone receptor expression in clinico-pathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-9.
29. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-2000.
30. Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J, MacCollin M. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 2005;162:135-9.
31. Peyrard M, Fransson I, Xie YG, Han FY, Ruttledge MH, Swahn S, Collins JE, Dunham I, Collins VP, Dumanski JP. Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Hum Mol Genet 1994;3:1393-9.
32. Lekanne Deprez RH, Riegman PH, Groen NA, Warrings UL, van Biezen NA, Molijn AC, Bootsma D, de Jong PJ, Menon AG, Kley JA, Seizinger BR, Zwarthoff EC. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 1995;10:1521-8.
33. Schmitz U, Mueller W, Weber M, Sevenet N, Delattre O, von Deimling A. IN11 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 2001;84:199-201.